옵션 체인은 다양한 행사가격과 만기일에 대한 Longevity Health Holdings의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Longevity Health Holdings에 대한 시장 심리를 평가합니다..

Longevity Health Holdings (NASDAQ:XAGE) 주식, 옵션 체인

Longevity Health Holdings

Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings Inc

Longevity Health Holdings, Inc. - Warrant

HSBC analyst Cenk Orcan upgrades Embraer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) from Hold to Buy and raises the price target from $45 to $57.

News

Upgrades

Price Target

Analyst Ratings

Embraer-Empresa Brasileira De Aeronautica

HSBC Upgrades Embraer to Buy, Raises Price Target to $57

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. The Agreement is now fully binding and HCW Biologics has earned the $7.0 million upfront license fee under the terms of the Agreement, as amended.

HCWB

HCW Biologics Says WY Biotech Confirm Commitment To Proceed With Development And Commercialization Of Licensed Molecule, HCW11-006, For In Vivo Therapeutic Applications

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that WY Biotech has completed its due diligence related to HCWB's technology transfer report, including the characterization of the cell line, delivered on May 13, 2025. In addition, WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. The Agreement is now fully binding and HCW Biologics has earned the $7.0 million upfront license fee under the terms of the Agreement, as amended.
In addition to the $7.0 million upfront payment, HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. Furthermore, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering.

HCW Biologics Secures $7M License Fee As WY Biotech Completes Due Diligence On HCW11-006

Macro Economic Events

Macro Notification

Econ #s

Economics

General

ADP Nonfarm Employment Change For May 37K Vs 111K Est.; 60K Prior

Stephens &amp; Co. analyst Todd Weller maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $450 to $540.

CRWD

Stephens & Co. Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $540

reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) ("reAlpha" or the "Company"), an AI-powered real estate technology company, today announced a strategic leadership transition to support its next phase of growth. Effective June 3, 2025, Mike Logozzo, President and Chief Operating Officer, has been appointed Chief Executive Officer, and Giri Devanur, reAlpha's founder, Chairman of the Board and former Chief Executive Officer, has assumed the role of Executive Chairman of the Board. As part of this transition, Mr. Logozzo will serve as Interim Chief Operating Officer until a successor is identified.
Since joining reAlpha, Mr. Logozzo has played a pivotal role in the company's momentum, serving as Chief Financial Officer and later as President and Chief Operating Officer. Under his guidance, reAlpha has expanded its national presence, launched the proprietary AI platform Claire, and enhanced its real estate, mortgage, and title capabilities. His proven success across operations, financial services, and innovation has been critical to reAlpha's ongoing advancement.

Management

AIRE

reAlpha Tech Corp. Appoints President And COO Mike Logozzo As New CEO, As Founder Giri Devanur Transitions To Executive Chairman Role; Logozzo To Also Serve As Interim COO During Leadership Search

Wolfe Research analyst Steve Fleishman maintains Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) with a Outperform and raises the price target from $335 to $350.

Wolfe Research Maintains Outperform on Cheche Group, Raises Price Target to $350

<a href="https://www.globenewswire.com/Tracker?data=vzdj-uBtDE9BfwfY4CNUyIvLcwyvR2fgom87L8iB02gZ160yifipO7kHmup1liDRd-B1JPSV-U4AOqhtt9S2tBO0FS35ROxMrh9H8J9CQW8=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the <a href="https://www.globenewswire.com/Tracker?data=JGOn-OYYoMVTp8heDhWiIuJKGHfmd48rqGv5eHQQ8kc7gAgrlFsj3_GgtDnF9APh7splsiW8lglZawZzHbn8CtJmJNQ5KHBPx0Iwr-01R86W9aI6wSu-probtX_Q0JQcxNJ1KPwxbyJZJlUjlcb_Imk8p1hYV0r6y6MGDMeckBQ=">Journal of the American Society of Nephrology</a> (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT).
The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that compared the safety and efficacy of vadadustat with darbepoetin alfa in adult patients with CKD-related anemia. Data from the pre-specified analyses for the U.S. patient subgroup demonstrate that among patients with DD-CKD, safety and efficacy of vadadustat and darbepoetin alfa in the U.S. and outside the U.S. were similar. Among the U.S. patient subgroup with NDD-CKD, safety and efficacy outcomes were similar, but the risk for major adverse cardiovascular event (MACE) with vadadustat was higher than darbepoetin alfa outside the United States. In these analyses, safety was measured by time to first MACE and efficacy was measured by mean change in hemoglobin. The article titled, "Safety and Efficacy of Vadadustat for the Treatment of CKD-Related Anemia within and outside the United States," is available <a href="https://www.globenewswire.com/Tracker?data=Q8EAVRvCjTfUeHUP9KZPv1XrVAofNmL7y37CuUJMd50apQdt2jSxjTuWAeIzImcKumpGwzv_CTAcPULWd7nBmc_JvEHVLGE99uMinZDXcjPFXAhtpm-tPAT2JysrmOo6498dIj5-E-5dobmq0yM9kBl2QtAIexVYRMZFKsZj-ng=">here</a>.
Vafseo&#xAE; (vadadustat) was approved by the U.S. Food and Drug Administration in March 2024 for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo has been available in the U.S. since January 2025.

Biotech

AKBA

Akebia Therapeutics Announces Publication In JASN Of U.S. And Non-U.S. Subgroup Analyses From Vadadustat Global Phase 3 Trials, Showing Comparable Safety And Efficacy In Dialysis-Dependent CKD Patients And Highlighting Elevated MACE Risk In U.S. Non–Dialysis-Dependent CKD Patients

Global

CUPR

Cuprina Holdings Announces Launch Of Saudi-Based Lab To Manufacture MEDIFLY Maggot Therapy For Chronic Wounds In MENA Region And Exclusive Rights To Distribute Medicinal Leeches Across GCC, Advancing Regional Expansion In Biomedical Treatments

Litchfield Hills analyst Theodore O'Neill initiates coverage on Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) with a Buy rating and announces Price Target of $5.

Initiation

RIME

Litchfield Hills Initiates Coverage On Algorhythm Holdings with Buy Rating, Announces Price Target of $5

AMOD

Alpha Modus Announces $31M Capital Structure Overhaul as CEO-Affiliated Trusts Convert Series C Preferred Into 26.5M Class A Shares

WIIM

ENSC

Ensysce Biosciences shares are trading higher after the company announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse.

Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) ("FangDD" or the "Company"), a customer-oriented property technology company in China, today announced that its share consolidation ("Share Consolidation"), involving the consolidation of every 16 ordinary shares with a par value of US$0.0005625 per share, into 1 ordinary share with a par value of US$0.009 per share,&nbsp;will take effect at 8:00 a.m. Eastern Time on June 9, 2025. The Company's Class A ordinary shares will open for trading on Nasdaq on June 9, 2025, on a post-split basis, under the existing ticker symbol "DUO," with a new CUSIP number of G33147128.

Stock Split

Fangdd Network Group Announces 1-for-16 Share Consolidation Effective June 9, 2025

Loop Capital analyst Alan Gould initiates coverage on Lionsgate Studios (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LION#NYSE">LION</a>) with a Hold rating and announces Price Target of $8.

LION

Loop Capital Initiates Coverage On Lionsgate Studios with Hold Rating, Announces Price Target of $8

Partnership milestone highlights success in transforming security operations with the Falcon platform and accelerating consolidation through Falcon Flex
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=2a2f5fa5168f9b1a11d9c9ad666f85e1">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) today announced it is the first cybersecurity independent software vendor (ISV) to surpass $1 billion in total sales through its partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidepointsecurity.com%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=GuidePoint+Security&amp;index=2&amp;md5=c5e35373cf4ddf0e8ee2ef9754062497">GuidePoint Security</a>, a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk.
As the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2Fglobal-threat-report%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=speed+and+sophistication+of+attacks&amp;index=3&amp;md5=6407130df0f346a8ab1f8d5518945bc6">speed and sophistication of attacks</a> accelerate and the skills gap widens, organizations are turning to cutting-edge AI-native technology and cybersecurity expertise to stay ahead of modern threats. CrowdStrike and GuidePoint Security are meeting this demand by combining the power of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=CrowdStrike+Falcon%26%23174%3B+cybersecurity+platform&amp;index=4&amp;md5=33317aceea503462fe19e05e7ac99ba2">CrowdStrike Falcon&#xAE; cybersecurity platform</a> with expert-led services to protect organizations of all sizes. GuidePoint is fueling rapid adoption by delivering scalable services built on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fnext-gen-siem%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=Falcon+Next-Gen+SIEM&amp;index=5&amp;md5=c9589c4b40dbb9d8c2424d6067e689a5">Falcon Next-Gen SIEM</a>, which unifies native and third-party data, real-time intelligence, and AI-driven automation to deliver comprehensive visibility, high-fidelity alerts, and machine speed response. With this disruptive technology, GuidePoint is helping organizations replace outdated systems, streamline security and IT data management, and stop breaches.
A key enabler of this success is <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2Fproducts%2Fbundles%2Ffalcon-flex%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=Falcon+Flex&amp;index=6&amp;md5=93f933c9e2970ce8a85a58b2aa75899e">Falcon Flex</a>, which provides adaptable licensing for the Falcon platform's full portfolio of best-in-class modules. This enables partners like GuidePoint to deliver greater value to customers by offering the flexibility to use what they need, when they need it. With Falcon Flex and Falcon Next-Gen SIEM, GuidePoint is making it easier for organizations worldwide to transform security operations and consolidate point products – meeting surging demand for the Falcon platform in the modern AI era.
"Our partnership with CrowdStrike is rooted in a shared mission: empowering organizations to confidently stop breaches," said Mark Thornberry, senior vice president, vendor management at GuidePoint Security. "This milestone reflects the value organizations place on scalable, AI-native cybersecurity solutions – and the trust they put in GuidePoint to deliver the right expertise and services around the Falcon platform to meet their evolving needs."
"GuidePoint has been a long-standing and trusted partner in our ecosystem, consistently delivering the expertise and services customers need to unlock the full potential of the Falcon platform," said Daniel Bernard, chief business officer at CrowdStrike. "Their focus on Falcon Next-Gen SIEM and recognition of the transformative value of Falcon Flex have enabled customers to streamline security operations, consolidate costs and stay ahead of evolving threats. Surpassing $1 billion reflects the strength of our partnership and the market's confidence in our shared ability to drive cybersecurity transformation."
GuidePoint Security was recently named <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidepointsecurity.com%2Fnewsroom%2Fguidepoint-security-wins-2025-crowdstrike-americas-falcon-flex-partner-of-the-year-award%2F&amp;esheet=54264965&amp;newsitemid=20250604670667&amp;lan=en-US&amp;anchor=CrowdStrike%26%238217%3Bs+2025+Americas+Falcon+Flex+Partner+of+the+Year&amp;index=7&amp;md5=39d55174c7ff5982818559fa89653729">CrowdStrike's 2025 Americas Falcon Flex Partner of the Year</a> for its demonstrated excellence in Falcon Flex performance. Together, the companies are enabling thousands of organizations to consolidate legacy tools, eliminate complexity, and strengthen security outcomes.

Retail Sales

CrowdStrike And GuidePoint Security Announces It Has Surpassed $1B In Sales Helped By Demand For Its Falcon Next-Gen SIEM

~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~
~ Funds Accelerate Path Towards Commercialization ~

Contracts

Ensysce Biosciences Secures $5.3M In Continued NIDA Support To Advance Opioid Overdose Protection

Scienjoy Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJ#NASDAQ">SJ</a>) reported quarterly losses of $(0.02) per share. This is a 166.67 percent decrease over earnings of $0.03 per share from the same period last year. The company reported $42.40 million in sales this quarter. This is a 3.21 percent decrease over sales of $43.81 million the same period last year.

Earnings

Scienjoy Holding Q1 Adj. EPS $(0.02) Down From $0.03 YoY, Sales $42.40M Down From $43.81M YoY

Final critical papers on RECOVER clinical study data accepted, supporting the Company&#39;s submission for coverage reconsideration
Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy
In-depth analysis on suicidality at 12 months yields positive results
LivaNova PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek reconsideration of national Medicare coverage for VNS Therapy&trade; in unipolar patients with treatment-resistant depression (TRD). The first step in the process for making a National Coverage Determination (NCD) is the submission of a draft formal request for CMS reconsideration.
Five critical articles featuring outcomes from in-depth data analyses on primary and select secondary endpoints in the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03887715&amp;esheet=54264845&amp;newsitemid=20250604572918&amp;lan=en-US&amp;anchor=RECOVER+study&amp;index=1&amp;md5=4c84474c3e9d43a81f85c2fbc475ab64">RECOVER study</a> have recently been published in or accepted by peer-reviewed journals, and the totality of data presented in these articles serves as the basis of the Company&#39;s request to CMS. The company believes these articles satisfy the Coverage with Evidence Development (CED) requirement of sharing peer-reviewed, publicly accessible results of pre-specified outcomes measured in the RECOVER study. In addition to the five articles, the request for coverage reconsideration includes strong 24-month clinical outcomes from the unipolar cohort of the RECOVER clinical study that demonstrate the substantial retention of benefits and the durability of VNS Therapy over time.

LIVN

LivaNova Initiates Process With U.S. CMS To Seek Reconsideration Of National Medicare Coverage For VNS Therapy In Unipolar Patients With Treatment-Resistant Depression

INAB

IN8bio To Effect 1-For-30 Reverse Stock Split

Small Cap Consumer Research analyst Eric Beder reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $4 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $4 Price Target

Press Releases

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Longevity Health Holdings, Inc. - XAGE

LONGEVITY HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Longevity Health Holdings, Inc. - XAGE

Comments

Longevity Health Holdings

Longevity Health Holdings (XAGE) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌